A V Global CO

A V Global CO is an Indian pharmaceutical exporter specializing in finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Established in 2007, the company is headquartered in New Delhi, India. It operates as a private limited company under the Corporate Identification Number (CIN) U63090DL2007PTC159315. The authorized capital stands at ₹5.00 crore, with a paid-up capital of ₹4.00 crore. The company employs approximately 243 professionals. Its registered address is 201, New Delhi House, Barakhamba Road, New Delhi, Delhi, 110001.

A V Global CO operates manufacturing facilities in India, focusing on the production of finished pharmaceutical formulations. Specific details regarding plant locations, capacities, and specializations are not publicly disclosed. The company's manufacturing processes adhere to industry standards to ensure product quality and compliance with regulatory requirements.

The leadership team of A V Global CO includes:

• Ashok Kumar Mehta: Director
• Vijay Mehta: Director

Both directors have been associated with the company since its inception in 2007. Their extensive experience in the pharmaceutical and logistics sectors contributes to the company's strategic direction and operational efficiency.

A V Global CO's export portfolio includes Codeine and Diphenhydramine, each valued at $450,000, contributing to a total export value of $900,000 across 18 shipments. These products fall under the therapeutic categories of Analgesics & Antipyretics and Antihistamines & Allergy, respectively. The company's market share in these categories is 0.4% for Codeine and 1.4% for Diphenhydramine. The top three therapeutic categories account for 50% each, indicating a balanced product portfolio. The company's portfolio concentration is high, with the top five products comprising 100% of its exports.

A V Global CO has established a presence in emerging markets, including Africa, Latin America, and Southeast Asia. The company's export data indicates shipments to countries such as Ghana, Benin, and Kenya, suggesting a strategic focus on these regions. While specific details regarding WHO prequalification are not available, the company's engagement in these markets implies efforts to meet international quality standards, facilitating access to these regions.

A V Global CO's export strategy demonstrates a concentration in specific therapeutic categories, with a balanced focus on Analgesics & Antipyretics and Antihistamines & Allergy. This approach indicates a targeted market strategy, potentially reducing diversification risks. The company's export activities in emerging markets reflect a strategic direction aimed at expanding its global footprint and leveraging growth opportunities in these regions.

Specific details regarding A V Global CO's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. The company's export data does not provide information on its presence in the U.S. market, suggesting limited or no direct engagement with the FDA-regulated market.

Information regarding A V Global CO's WHO prequalification, EU Good Manufacturing Practice (GMP) certificates, and European Directorate for the Quality of Medicines & HealthCare (EDQM) status is not publicly disclosed. The company's export data does not indicate certifications from these international regulatory bodies, which are often essential for market access in Europe and other regions.

A V Global CO holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), the national regulatory authority in India. Specific details regarding state drug controller approvals and export No Objection Certificates (NOCs) are not publicly available. The company's compliance with CDSCO regulations underscores its commitment to maintaining quality standards in its manufacturing processes.

There are no publicly available records of Form 483 observations, warning letters, or import alerts issued to A V Global CO. The absence of such records suggests that the company maintains a clean regulatory compliance history.

A V Global CO operates in the pharmaceutical export sector, focusing on finished formulations in the Analgesics & Antipyretics and Antihistamines & Allergy categories. The company's export data indicates a total export value of $900,000 across 18 shipments, with a portfolio concentration of 100% in its top five products. While specific market share data is not available, the company's strategic focus on these therapeutic categories positions it within a competitive landscape that includes both large multinational corporations and other specialized exporters.

A V Global CO's key differentiators include its specialized focus on finished pharmaceutical formulations, particularly in the Analgesics & Antipyretics and Antihistamines & Allergy categories. The company's export strategy targeting emerging markets demonstrates its adaptability and commitment to expanding its global presence. Additionally, the absence of publicly available regulatory compliance issues reflects positively on its operational integrity.

A V Global CO's current strategic direction appears to be focused on exporting finished pharmaceutical formulations, with a particular emphasis on specific therapeutic categories. The company's engagement in emerging markets suggests a strategy aimed at diversifying its market presence and leveraging growth opportunities. Future outlooks would benefit from obtaining international certifications such as WHO prequalification and EU GMP to enhance market access and competitiveness.

A V Global CO has demonstrated a consistent track record in exporting pharmaceutical formulations, with a total export value of $900,000 across 18 shipments. The company's portfolio concentration indicates a focused approach to its product offerings. While specific reliability indicators are not publicly available, the absence of regulatory compliance issues and the company's strategic focus on emerging markets suggest a reliable and committed supplier.

Importers should verify the following certifications to ensure product quality and regulatory compliance:

• FDA Registration: To confirm compliance with U.S. regulations. Verification can be done through the FDA's official website.

• WHO-GMP Certification: To ensure adherence to international manufacturing standards. Verification can be done through the World Health Organization's official website.

• EU GMP Certification: To confirm compliance with European manufacturing standards. Verification can be done through the European Medicines Agency's official website.

• ISO Certification: To ensure adherence to international quality management standards. Verification can be done through the International Organization for Standardization's official website.

Importers should undertake the following steps to ensure a thorough evaluation of A V Global CO:

• Verify Regulatory Certifications: Confirm the validity of FDA, WHO-GMP, EU GMP, and ISO certifications.

• Assess Product Quality: Request samples and review quality control processes.

• Evaluate Financial Stability: Review financial statements and credit reports.

• Check Compliance History: Investigate any past regulatory issues or compliance violations.

• Review Supply Chain Practices: Assess sourcing, manufacturing, and distribution practices for transparency and reliability.

Red flags to watch for include expired or invalid certifications, inconsistent product quality, financial instability, and a history of regulatory non-compliance. Recommended pre-order checks involve obtaining and verifying all relevant certifications, conducting quality assessments, and ensuring clear communication regarding terms and conditions.